V559A and N822I double KIT mutant melanoma with predictable response to imatinib?

Pigment Cell and Melanoma Research

Volumn 24, Issue 2, 2011, Pages 390-392

  Mcdonnell, Kevin ^a   Betz, Bryan ^b   Fullen, Douglas ^b   Lao, Christopher D ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; PROTEIN TYROSINE KINASE INHIBITOR;

AGED; CANCER CHEMOTHERAPY; CANCER SIZE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE TITRATION; DRUG RESISTANCE; DRUG RESPONSE; DYSPNEA; EXON; FATIGUE; FEMALE; GENE MUTATION; HUMAN; INGUINAL LYMPH NODE; LEG EDEMA; LETTER; LIGAND BINDING; LOW DRUG DOSE; LUNG METASTASIS; LUNG NODULE; MELANOMA; METASTASIS; ONCOGENE C KIT; RECTUM INJURY; STOMACH TUMOR;

AGED, 80 AND OVER; DRUG RESISTANCE, NEOPLASM; FATAL OUTCOME; FEMALE; HUMANS; MELANOMA; MUTATION; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES;

EID: 79952587640     PISSN: 17551471     EISSN: 1755148X     Source Type: Journal    
DOI: 10.1111/j.1755-148X.2010.00822.x     Document Type: Letter

References (26)

1. Antonescu, C.R., Besmer, P., Guo, T. et al. (2005). Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin. Cancer Res., 11, 4182-4190.
2. Carvajal, R., Chapman, P.B., Wolchok, J.D., Cane, L., Teitcher, J.B., Lutzky, J., Pavlick, A.C., Bastian, B.C., Antonescu, C.R., and Schwartz, G.K. (2009). A phase II study of imatinib mesylate (IM) for patients with advanced melanoma harboring somatic alterations of KIT. J. Clin. Oncol., 25, 9001.
3. Carvajal, R., Chapman, P., Wolchok, J., Cane, L., Teitcer, J., Lutzky, J., Pavlick, A., Bastian, B., Antonescu, R., and Schwartz, G. (2009). A phase II study of imatinin mesylate (IM) for patients with advanced melanoma harboring somatic alterations of KIT. J. Clin. Oncol., 27, 15s.
4. Chan, C., Chen, L., Hsueh, Y., Chuang, W., Lee, H., Huang, M., Heieh, R., and Weng, W. (2009). Differential response of primary or secondary exon 13/14 and exon 17 c-kit mutant to nilotinib and sunitinib: findings from a cell-based drug-screening platform. J. Clin. Oncol., 27, Suppl; abstract e15636.
5. Chen, L.L., Trent, J.C., Wu, E.F. et al. (2004). A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res., 64, 5913-5919.
6. Corless, C.L., and Heinrich, M.C. (2008). Molecular pathobiology of gastrointestinal stromal sarcomas. Annu. Rev. Pathol., 3, 557-586.
7. Curtin, J.A., Fridlyand, J., Kageshita, T. et al. (2005). Distinct sets of genetic alterations in melanoma. N. Engl. J. Med., 353, 2135-2147.
8. Curtin, J.A., Busam, K., Pinkel, D., and Bastian, B.C. (2006). Somatic activation of KIT in distinct subtypes of melanoma. J. Clin. Oncol., 24, 4340-4346.
9. Debiec-Rychter, M., Cools, J., Dumez, H. et al. (2005). Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. Gastroenterology, 128, 270-279.
10. Debiec-Rychter, M., Sciot, R., Le Cesne, A. et al. (2006). KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur. J. Cancer, 42, 1093-1103.
11. Gramza, A.W., Corless, C.L., and Heinrich, M.C. (2009). Resistance to tyrosine kinase inhibitors in gastrointestinal stromal tumors. Clin. Cancer Res., 15, 7510-7518.
12. Grimpen, F., Yip, D., Mcarthur, G., Waring, P., Goldstein, D., Loughrey, M., Beshay, V., and Chong, G. (2005). Resistance to imatinib, low-grade FDG-avidity on PET, and acquired KIT exon 17 mutation in gastrointestinal stromal tumour. Lancet Oncol., 6, 724-727.
13. Growney, J.D., Clark, J.J., Adelsperger, J., Stone, R., Fabbro, D., Griffin, J.D., and Gilliland, D.G. (2005). Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412. Blood, 106, 721-724.
14. Heinrich, M.C., Corless, C.L., Demetri, G.D. et al. (2003). Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J. Clin. Oncol., 21, 4342-4349.
15. Heinrich, M.C., Corless, C.L., Blanke, C.D. et al. (2006). Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J. Clin. Oncol., 24, 4764-4774.
16. Hodi, F.S., Friedlander, P., Corless, C.L. et al. (2008). Major response to imatinib mesylate in KIT-mutated melanoma. J. Clin. Oncol., 26, 2046-2051.
17. Kemmer, K., Corless, C.L., Fletcher, J.A., Mcgreevey, L., Haley, A., Griffith, D., Cummings, O.W., Wait, C., Town, A., and Heinrich, M.C. (2004). KIT mutations are common in testicular seminomas. Am. J. Pathol., 164, 305-313.
18. Lutzky, J., Bauer, J., and Bastian, B.C. (2008). Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation. Pigment Cell Melanoma Res., 21, 492-493.
19. Redaelli, S., Piazza, R., Rostagno, R., Magistroni, V., Perini, P., Marega, M., Gambacorti-Passerini, C., and Boschelli, F. (2009). Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. J. Clin. Oncol., 27, 469-471.
20. Satzger, I., Kuttler, U., Volker, B., Schenck, F., Kapp, A., and Gutzmer, R. (2010). Anal mucosal melanoma with KIT-activating mutation and response to imatinib therapy - case report and review of the literature. Dermatology, 220, 77-81.
21. Tamborini, E., Bonadiman, L., Greco, A. et al. (2004). A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient. Gastroenterology, 127, 294-299.
22. Torres-Cabala, C.A., Wang, W.L., Trent, J. et al. (2009). Correlation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acral-lentiginous/mucosal type. Mod. Pathol., 22, 1446-1456.
23. Wardelmann, E., Thomas, N., Merkelbach-Bruse, S., Pauls, K., Speidel, N., Buttner, R., Bihl, H., Leutner, C.C., Heinicke, T., and Hohenberger, P. (2005). Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations. Lancet Oncol., 6, 249-251.
24. Wardelmann, E., Merkelbach-Bruse, S., Pauls, K. et al. (2006). Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate. Clin. Cancer Res., 12, 1743-1749.
25. Went, P.T., Dirnhofer, S., Bundi, M. et al. (2004). Prevalence of KIT expression in human tumors. J. Clin. Oncol., 22, 4514-4522.
26. Woodman, S.E., and Davies, M.A. (2010). Targeting KIT in melanoma: a paradigm of molecular medicine and targeted therapeutics. Biochem. Pharmacol., 80, 568-574.